/
Other
Neoadjuvant Therapy
63
Pipeline Programs↗
61
Active Trials↗
28
Companies Involved↗
Neoadjuvant Therapy is a moderately active landscape with 63 programs across 28 companies. The most active players are Shanghai Henlius Biotech, Suzhou Suncadia Biopharmaceuticals Co., Ltd.. 8 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 16
Phase 247
Phase 38
Approved
No programs
Analysis
Modality Breakdown
71%
Small molecule
42 of 59 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 59 classified programs, each share of the total. Modality classified for 100% of 63 pipeline programs.
Analysis
Trial Status
78
clinical trials
Recruiting29 · 37%
Not yet recruiting26 · 33%
Unknown status8 · 10%
Completed7 · 9%
Active, not recruiting5 · 6%
Withdrawn2 · 3%
Other1 · 1%
Clinical Trials
Trial Activity
78 trials
Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05941338·100 enrolled
Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
Recruiting·—·N/A·NCT06700382·1,166 enrolled
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
Recruiting·—·Phase 2·NCT07492342·30 enrolled
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Recruiting·—·Phase 2·NCT06420440·160 enrolled
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT05429463·250 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)